Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Acute Lymphoblastic Leukemia
25%
Acute Lymphocytic Leukemia
91%
Allele
16%
B Cell
100%
Cell Survival
8%
Childhood Cancer
8%
Childhood Leukemia
100%
Combination Therapy
25%
Cytokine Receptor
8%
Drug Resistance
8%
Gene Expression
8%
Gene Mutation
8%
Health Disparity
100%
Immunity
16%
Leukemia
8%
Leukemia Cell
16%
Mammalian Target of Rapamycin
25%
Pediatrics
8%
Pediatrics Patient
16%
Personalized Medicine
8%
Precursor
100%
Receptor
8%
Recurrence Risk
8%
Therapy Effect
16%
Tumor Suppressor Protein
41%
Xenograft
50%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
60%
Childhood Cancer
20%
Childhood Leukemia
100%
Combination Therapy
60%
Cytokine Receptor
20%
Drug Resistance
20%
Health Disparity
100%
Leukemia
60%
Normal Human
20%
Preclinical Study
20%
Receptor
20%
Recurrence Risk
20%
Therapeutic Effect
40%
Thymic Stromal Lymphopoietin
60%
Tumor Suppressor Protein
100%
Keyphrases
Acute Lymphoblastic Leukemia
16%
B-cell Precursor ALL
61%
B-cell Precursors
5%
Cancer Disparities
5%
Cell Survival
5%
Chemoresistance
5%
Childhood Cancer
5%
Childhood Leukemia
100%
Combination Therapy
11%
CRLF2
100%
CX-4945
5%
Cytokine Receptor
5%
Functional Defects
5%
Gene Expression
5%
Genetic Modification
5%
Health Disparities
100%
High Risk
5%
Hispanic
22%
Hispanic children
16%
Hispanic Patients
5%
IKZF1
5%
Immune-deficient Mice
11%
In Vivo Efficacy
5%
JAK-STAT
5%
Leukemia
5%
Leukemia Cells
5%
Mammalian Target of Rapamycin (mTOR)
11%
MTOR Pathway
5%
Non-Hispanic White
5%
Normal Human Serum
5%
Novel Therapies
5%
Novel Treatments
5%
Overexpression
5%
Patient Samples
5%
Patient-derived Xenograft
33%
Pediatric
5%
Pediatric Patients
11%
Precision Medicine
5%
Primary Leukemia Cells
5%
Relapse Rate
5%
Serum Levels
5%
Specific Inhibitor
5%
Standard Patient
5%
Target Pathways
5%
Therapeutic Effect
11%
Therapeutic Efficacy
5%
Tumor Suppressor
11%
Tumor Suppressor Activity
16%